A Randomized, Double-blind, Placebo-controlled, Ascending Single Oral Dose, Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics of KD101 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 08 Jul 2017
At a glance
- Drugs KD 101 (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Kwang Dong Pharmaceutical
- 11 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Mar 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Apr 2014 to 1 Aug 2014.
- 11 Mar 2014 According to the ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.